Contract Small Molecule API Manufacturing Industry by the Numbers – 2019 PharmSource Edition

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

This report characterizes the contract small molecule active pharmaceutical ingredient (API) manufacturing industry through a number of quantitative dimensions, including number and type of participants, containment and controlled substance capabilities, and financial performance of the top public contract manufacturing organizations (CMOs). Contract Small Molecule API Manufacturing is critical for establishing an understanding of the small molecule API CMO industry and the features of some of the largest CMOs participating in the industry.

Scope

Who should buy this report?

This 44-page report gives important, expert insight you won’t find in any other source. 26 tables and figures throughout the report illustrate major points and trends. This report is required reading for:

• CMO executives who must have deep understanding of the small molecule API marketplace to make strategic planning and investment decisions.

• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.

• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

Overview of contract small molecule API facilities and the proportion of containment and controlled substance specialist capabilities

Detailed view of the geographic distribution of the small molecule API facilities

Establishing which CMOs are most involved in contract small molecule API industry by facility count

Analysis of M&A activity related to small molecule API facilities

Aarti Drugs Ltd
Aarti Industries Ltd
Abbott Laboratories
AbbVie Inc
Acacia Life Sciences Pvt Ltd
Aceto Corp
Advent International Corp
Agilent Technologies Inc
Ajinomoto Co Inc
Akzo Nobel NV
Albany Molecular Research Inc
Albemarle Corp
Alcami Corp
Alembic Pharmaceuticals Ltd
Alkali Metals Ltd
Alkem Laboratories Ltd
Allergan Plc
Altasciences
AMAG Pharmaceuticals Inc
Amgen Inc
AMPAC Fine Chemicals LLC
Amphastar Pharmaceuticals Inc
Antibiotice SA
Anuh Pharma Ltd
Apeloa Co Ltd
Apiscent Labs LLC
Aptuit LLC
Arc Trinova Ltd
Arch Pharmalabs Ltd
Arkema SA
Aspen Pharmacare Holdings Ltd
Astellas Pharma Inc
AstraZeneca Plc
Audax Private Equity
Auro Laboratories Ltd
Aurobindo Pharma Ltd
Avara Pharmaceutical Services Inc
Avista Pharma Solutions Inc
Bachem Holding AG
Bain Capital Private Equity
LP
Bajaj Healthcare Ltd
BASF SE
Bausch Health Companies Inc
Baxter International Inc
Bayer AG
Beximco Pharmaceuticals Ltd
BGF Investments LP
Biocon Ltd
Biotika AS
Bristol-Myers Squibb Co
C² PHARMA S.à r.l
Cadila Healthcare Ltd
Cambrex Corp
Catalent Inc
Centrient Pharmaceuticals
Changzhou Qianhong Bio-Pharma Co Ltd
Chunghwa Chemical Synthesis & Biotech Co Ltd
Church & Dwight Co Inc
Cipla Ltd
CKD Bio Corp
Companhia Industrial Produtora de Antibioticos SA
Cook Pharmica LLC
Corbion NV
CordenPharma International
Covance Inc
CVC Capital Partners Fund VI
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Daito Pharmaceutical Co Ltd
Dawnrays Pharmaceutical (Holdings) Ltd
Deva Holding AS
Divi's Laboratories Ltd
Dr. Reddy's Laboratories Ltd
Edgewater Capital Partners
Eisai Co Ltd
Eli Lilly and Co
Ercros SA
EstechPharma Co Ltd
Everest Organics Ltd
Everlight Chemical Industrial Corp
Evonik Industries AG
Evotec AG
F. Hoffmann-La Roche Ltd
Fareva SA
FDC Ltd
Formosa Laboratories Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Granules India Ltd
H. Lundbeck AS
Hainan Shuangcheng Pharmaceuticals Co Ltd
Halo Pharma Inc
Hanmi Pharmaceuticals Co Ltd
High Tech Pharm Co Ltd
Hikal Ltd
Hikma Pharmaceuticals Plc
Huadong Medicine Co Ltd
IDT Australia Ltd
Inabata & Co Ltd
Indoco Remedies Ltd
Ind-Swift Laboratories Ltd
Insys Therapeutics Inc
International Isotopes Inc
IOL Chemicals and Pharmaceuticals Ltd
IPCA Laboratories Ltd
Ipsen SA
J B Chemicals and Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Ltd
Jazz Pharmaceuticals Plc
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Lianhuan Pharmaceutical Co Ltd
Jiangxi Fushine Pharmaceutical Co Ltd
Jiangxi Synergy Pharmaceutical Co Ltd
Johnson & Johnson
Johnson Matthey Plc
Kaneka Corp
Kemwell Biopharma Pvt Ltd
Kingchem Life Science LLC
Krebs Biochemicals & Industries Ltd
Kyowa Hakko Kirin Co Ltd
Laboratorios Farmaceuticos Rovi SA
Lannett Company Inc
Laurus Labs Ltd
LG Chem Ltd
Lianhe Chemical Technology Co Ltd
Livzon Pharmaceutical Group Co Ltd
Lonza Group Ltd
Lupin Ltd
MallInckrodt Plc
Mercachem-Syncom Group
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
MilliporeSigma
Minakem SAS
Mitsubishi Tanabe Pharma Corp
Morepen Laboratories Ltd
Motilal Oswal Private Equity Advisors Private Limited; Rosewood Private Investments
Mylan NV
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Nantong Jinghua Pharmaceutical Co Ltd
Natco Pharma Ltd
Nectar Lifesciences Ltd
Nektar Therapeutics
Neuland Laboratories Ltd
Nippon Fine Chemical Co Ltd
Nissan Chemical Corp
Noramco
North China Pharmaceutical Co Ltd
Northeast Pharmaceutical Group Co Ltd
Novartis AG
Novo Nordisk AS
Olon SpA
Orchid Pharma Ltd
Otsuka Holdings Co Ltd
Parabolic Drugs Ltd
Patheon NV
PCAS
Permira
Perrigo Co Plc
Pfizer Inc
PharmaCore Inc
Pharmaron Beijing Co Ltd
Piramal Enterprises Ltd
Pisgah Labs Inc
Porton Pharma Solutions Ltd
Punjab Chemicals & Crop Protection Ltd
Purdue Pharma LP
Recipharm AB
Reckitt Benckiser Group Plc
Recordati SpA
Recro Pharma Inc
Richter Gedeon Nyrt
Royal DSM NV
SAI Life Sciences Ltd
Sandoz GmbH
Sanochemia Pharmazeutika AG
Sanofi
Savior Lifetec Corp
SCI Pharmtech Inc
ScinoPharm Taiwan Ltd
SeQuent Scientific Ltd
Seven Star Pharmaceutical Co Ltd
Shandong Xinhua Pharmaceutical Co Ltd
Sharon Bio-Medicine Ltd
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Shilpa Medicare Ltd
Shionogi & Co Ltd
SI Group Inc
Siegfried Holding AG
SK Biotek Co Ltd
SK Capital Partners
Smruthi Organics Ltd
SMS Pharmaceuticals Ltd
Solara Active Pharma Sciences Ltd
Solvay SA
Sopharma AD
ST Pharm Co Ltd
Standard Chem & Pharm Co Ltd
Sterling Pharma Solutions Ltd
Strides Pharma Science Ltd
Sumitomo Chemical Co Ltd
Sun Pharmaceutical Industries Ltd
Suven Life Sciences Ltd
Syncom BV
Syngene International Ltd
Synmosa Biopharma Corp
Takeda Pharmaceutical Co Ltd
Tasmanian Alkaloids Pty Ltd
Terumo Corp
Teva Pharmaceutical Industries Ltd
The Carlyle Group
Tokuyama Corp
Torrent Pharmaceuticals Ltd
TPG Capital LP
TPI Enterprises
Tyche Industries Ltd
Ube Industries Ltd
UCB SA
Umicore NV
Unichem Laboratories Ltd
UniTao Pharmaceuticals LLC
Vistin Pharma AS
Wacker Chemie AG
Wanbury Ltd
Yakult Honsha Co Ltd
Yuki Gosei Kogyo Co Ltd
Yung Zip Chemical Ind Co Ltd
Zentiva Group as
Zhejiang Cheng Yi Pharmaceutical Co Ltd
Zhejiang Hisoar Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Huahai Pharmaceutical Co Ltd
Zhejiang Jingxin Pharmaceutical Co Ltd
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Zhejiang Medicine Co Ltd
Zhejiang Starry Pharmaceutical Co Ltd
Zhejiang Tianyu Pharmaceutical Co Ltd
Zhejiang Xianju Pharmaceutical Co Ltd
Zhejiang Yongtai Technology Co Ltd

Table of Contents

1 Table of Contents

2 List of Tables

3 List of Figures

4 Executive Summary

5 Industry Size and Structure

5.1 Definition of the Small Molecule API CMO Universe

5.2 Industry Demographics

6 Top CMOs by Small Molecule API Facilities

6.1 Controlled Substance Small Molecule API Manufacturing Facilities

6.2 Small Molecule API Manufacturing Facilities with Containment

7 Geographical Distribution of Small Molecule Manufacturing Facilities

7.1 Geographical Distribution of Controlled Substance Facilities

7.2 Geographical Distribution of Facilities with Containment Capabilities

7.3 European Analysis

8 Characteristics of the Largest CMOs

9 M&A Activity Involving Small Molecule Contract Manufacturing Facilities

10 The Outlook for the API CMO Industry

11 Notes on Methodology

12 Appendix

12.1 Appendix Tables

12.2 Bibliography

12.3 Primary Research – Key Opinion Leaders in this Report

12.4 About the Authors

12.5 Contact Us

12.6 Disclaimer

Table

Table 1: Revenue Composition and Specialized Capabilities of Leading CMOs, 2018 25

Table 2: Percentage of Companies by Revenue Tier with Specialized Capabilities (Dedicated Contract and Public CMOs Only)

Table 3: CMO Small Molecule API Manufacturing Facility Acquisitions, 2015–2018 30

Table 4: CMO Small Molecule API Manufacturing Facilities Acquired by Company M&A and Divestment, 2015–2018 30

Table 5: CMO Small Molecule API Manufacturing Facilities Acquired by PE, 2015–2018 31

Table 6: Geographic Reach of CMOs with Small Molecule API Manufacturing, 2018 35

Table 7: Public CMOs’ API Manufacturing Facilities and Controlled Substance/Containment Capabilities, 2018 40

Figures

Figure 1: Geographic Reach of the Small Molecule API CMO Universe, 2018 (Public CMOs Only) 7

Figure 2: Public CMOs with Small Molecule Manufacturing Capability by Annual Contract Revenue, 2018 8

Figure 3: Geographic Distribution by Headquarters of Public Small Molecule API Dedicated Contract CMOs 9

Figure 4: Top CMOs by Small Molecule API Manufacturing Facilities 10

Figure 5: Top CMOs by Small Molecule API Facilities with Containment Capabilities 11

Figure 6: Top CMOs by Small Molecule API Facilities with Controlled Substance Capabilities 12

Figure 7: Oncology Pipeline by Developmental Stage and Molecule Type 14

Figure 8: Geographical Distribution of All CMO Small Molecule API Manufacturing Facilities 15

Figure 9: Geographical Distribution of Controlled Substance Small Molecule Manufacturing Facilities 17

Figure 10: Geographical Distribution of Small Molecule Manufacturing Facilities with Containment Capabilities 19

Figure 11: NMEs Requiring Special Handling, 2008–2018 20

Figure 12: Geographical Distribution of Small Molecule Contract Manufacturing Facilities in Europe, 2018 21

Figure 13: Distribution of European Small Molecule Contract Manufacturing Facilities with Containment Capabilities, 2018 22

Figure 14: Distribution of Controlled Substance European Small Molecule Contract Manufacturing Facilities, 2018 22

Figure 15: Public CMOs with Small Molecule Manufacturing Capability by Accumulated Contract Revenue, 2018 24

Figure 16: CMO Small Molecule API Manufacturing Facility with Containment Acquisitions, 2015–2018 27

Figure 17: Controlled Substance CMO Small Molecule API Manufacturing Facility Acquisitions, 2015–2018 27

Figure 18: All M&A Deals Involving Small Molecule API Containment Facilities, by Most Active CMOs, 2015–2018 28

Figure 19: All M&A Deals Involving Small Molecule API Controlled Substance Facilities, by Most Active CMOs, 2015–2018 29

Frequently asked questions

Contract Small Molecule API Manufacturing Industry by the Numbers – 2019 PharmSource Edition thematic reports
Currency USD
$4,995

Can be used by individual purchaser only

$14,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Contract Small Molecule API Manufacturing Industry by the Numbers – 2019 PharmSource Edition was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Contract Small Molecule API Manufacturing Industry by the Numbers – 2019 PharmSource Edition in real time.

  • Access a live Contract Small Molecule API Manufacturing Industry by the Numbers – 2019 PharmSource Edition dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.